Adaptation of WHO’s generic tuberculosis patient cost instrument for a longitudinal study in Africa

References

• Boccia D, Bond V. The catastrophic cost of tuberculosis: advancing research and solutions. Int J Tuberc Lung Dis. 2019;23:1129–10.
   Web of Science ®Google Scholar
• Tuberculosis patient cost surveys: a handbook. WHO/HTM/TB/2017.24. Geneva: World Health Organization; 2017 [cited 2020 Nov 26]. Available from: http://who.int/tb/publications/patient_cost_surveys/en/
   Google Scholar
• End TB Strategy. Geneva: World Health Organization; 2018. Available from: https://www.who.int/tb/post2015_TBstrategy.pdf?ua=1
   Google Scholar
• Global Tuberculosis Report. Geneva: World Health Organization; 2019 [cited 2020 Nov 26]. Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1
   Google Scholar
• Pedrazzoli D, Borghi J, Viney K, et al. Measuring economic burden for tuberculosis patients: end TB strategy and universal health coverage framework. Int J Tuberc Lung Dis. 2019;23:5–11.
   Web of Science ®Google Scholar
• Erlinger S, Stracker N, Hanrahan C, et al. Tuberculosis patients with higher levels of poverty face equal or greater costs of illness. Int J Tuberc Lung Dis. 2019;23:1205–1212.
   Web of Science ®Google Scholar
• WHO Global Task Force on TB Impact Measurement - Progress update. May 2020. Geneva: World Health Organization; 2020 [cited 2020 Nov 26]. Available from: https://www.who.int/tb/areas-of-work/monitoring-evaluation/impact_measurement_taskforce/en/
   Google Scholar
• Stracker N, Hanrahan C, Mmolawa L, et al. Risk factors for catastrophic costs associated with tuberculosis in rural South Africa. Int J Tuberc Lung Dis. 2019;23:756–763.
   PubMed Web of Science ®Google Scholar
• Luis Castro J. Lung health and well-being after TB: treating – and preventing – long-term health consequences. Message from the executive director: TB union; 2019 Jun [cited 2020 Nov 26]. Available from: https://www.theunion.org/who-we-are/the-directors-corner/the-directors-corner-300520
   Google Scholar
• Rachow A, Ivanova O, Wallis R, et al. TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB - a study protocol. BMC Pulm Med. 2019;19:4.
   PubMed Web of Science ®Google Scholar
• National Tuberculosis Management Guidelines. Department of Health, South Africa; 2014 [cited 2020 Nov 26]. Available from: https://aidsfree.usaid.gov/sites/default/files/tb_south-africa_adult_2014.pdf
   Google Scholar
• Management of Drug-resistant Tuberculosis. Department of Health, South Africa; [ updated 2013 Jan; [cited 2020 Nov 26]. Available from: https://health-e.org.za/wp-content/uploads/2014/06/MDR-TB-Clinical-Guidelines-Updated-Jan-2013.pdf
   Google Scholar
• Treatment of tuberculosis guidelines. 4th ed. Geneva: World Health Organization; 2020 [cited 2020 Nov 26]. Available from: https://apps.who.int/iris/bitstream/handle/10665/44165/9789241547833_eng.pdf;jsessionid=D2F5BA65C843273CDAA8ED82CF69A2C1?sequence=1
   Google Scholar
• National AIDS Control Programme (NACP). 4th ed. National Guidelines for the Management of HIV and 750 AIDS. The United Republic of Tanzania Ministry of Health and Social Welfare Tanzania Mainland; 2012 [cited 2020 Nov 26]. Available from: https://aidsfree.usaid.gov-/sites/default/files/hts_policy_tanzania.pdf
   Google Scholar
• Berry KM, Rodriguez CA, Berhanu RH, et al. Treatment outcomes among children, adolescents, and adults on treatment for tuberculosis in two metropolitan municipalities in Gauteng Province, South Africa. BMC Public Health. 2019;19:973.
   Web of Science ®Google Scholar
• World Health Organization. The shorter MDR-TB regimen. May 2016. Geneva: World Health Organization; 2020 [cited 2020 Nov 26]. Available from: https://www.who.int/tb/Short_MDR_regimen_factsheet.pdf
   Google Scholar
• World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019 [cited 2020 Nov 26]. Available from https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1
   Google Scholar
• Sweeney S, Mukora R, Candfield S, et al. Measuring income for catastrophic cost estimates: limitations and policy implications of current approaches. Soc Sci Med. 2018;215:7–15.
   PubMed Web of Science ®Google Scholar
• Hirasen K, Evans D, Govathson C, et al. Catastrophic costs for TB patients before treatment starts – results from a multi-country observational cohort study in sub-Saharan Africa. 51st Union World Conference on Lung Health; 2020 Oct 20-24. Abstract EP28-368-23.
   Google Scholar
• Guo Y, Logan HL, Glueck DH, et al. Selecting a sample size for studies with repeated measures. BMC Med Res Methodol. 2013;13:100.
   PubMed Web of Science ®Google Scholar
• Laurence YV, Griffiths UK, Vassall A. Costs to health services and the patient of treating tuberculosis: a systematic literature review. Pharmacoeconomics. 2015;33:939–955.
   PubMed Web of Science ®Google Scholar
• Richard Ernst. Indirect costs and cost-effectiveness analysis. Value Health. 2006;9(4): 1098-3015/06/253 253–261.
   Web of Science ®Google Scholar
• Victor B, Blevins M, Green AF, et al. Multidimensional poverty in rural Mozambique: a new metric for evaluating public health interventions. PLoS One. 2014;9:e108654.
   PubMed Web of Science ®Google Scholar
• Tanimura T, Jaramillo E, Weil D, et al. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J. 2014;43:1763–1775.
   PubMed Web of Science ®Google Scholar